Immunocore Holdings plc(IMCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMCR Immunocore Holdings plc

Trading 08-21 13:00:25 EDT

36.88

+0.60

+1.65%

High36.96	Low35.68	Vol117.01K
Open36.70	D1 Closing36.28	Amplitude3.51%
Mkt Cap1.90B	Tradable Cap1.69B	Total Shares51.50M
T/O4.28M	T/O Rate0.26%	Tradable Shares45.83M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMCR","market":"US","secType":"STK","nameCN":"Immunocore Holdings plc","latestPrice":36.88,"timestamp":1787331614213,"preClose":36.28,"halted":0,"volume":117011,"delay":0,"changeRate":0.016538037486218342,"floatShares":45834900,"shares":51498617,"eps":-0.356599,"marketStatus":"Trading","change":0.6,"latestTime":"08-21 13:00:25 EDT","open":36.7,"high":36.955,"low":35.68,"amount":4276844.839723,"amplitude":0.035143,"askPrice":36.88,"askSize":100,"bidPrice":36.79,"bidSize":226,"shortable":3,"etf":0,"ttmEps":-0.356599,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787342400000},"marketStatusCode":2,"adr":0,"adrRate":1,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":36.28,"preHourTrading":{"tag":"盘前","latestPrice":37.5,"preClose":36.28,"latestTime":"07:03 EDT","volume":1000,"amount":37500,"timestamp":1787310234488,"change":1.22,"changeRate":0.033627,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":36.28,"preClose":36.28,"latestTime":"19:30 EDT","volume":4774,"amount":173200.72,"timestamp":1787268609174,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.461195,"impliedVol":0.6133,"impliedVolPercentile":0.8964},"requestUrl":"/m/hq/s/IMCR/tweets","defaultTab":"tweets","newsList":[{"id":"2660437147","title":"Is Immunocore Holdings (IMCR) Undervalued After Stronger Revenue And Profitability Results?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660437147","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660437147?lang=en_us&edition=fundamental","pubTime":"2026-08-18 05:25","pubTimestamp":1787001921,"startTime":"0","endTime":"0","summary":"Immunocore Holdings (IMCR) reported its second quarter and six month results on August 6, 2026, with higher revenue and a move from a net loss to net income over the half year period.\nSee our latest analysis for Immunocore Holdings.\nAt a share price of US$34.21, Immunocore Holdings shows a 90 day share price return of 18.25%, while the 1 year total shareholder return of 5.88% contrasts with a 3 year total shareholder return that is down 42.85%. This suggests that momentum has been rebuilding...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/is-immunocore-holdings-imcr-undervalued-after-stronger-reven","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/is-immunocore-holdings-imcr-undervalued-after-stronger-reven","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IMCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657418356","title":"Immunocore price target raised to $43 from $40 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2657418356","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657418356?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:40","pubTimestamp":1786110056,"startTime":"0","endTime":"0","summary":"Morgan Stanley raised the firm’s price target on Immunocore (IMCR) to $43 from $40 and keeps an Equal Weight rating on the shares. Published first ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunocore-price-target-raised-to-43-from-40-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunocore-price-target-raised-to-43-from-40-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","IMCR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657645754","title":"Analysts Offer Insights on Healthcare Companies: Viatris (VTRS), Immunocore Holdings (IMCR) and Praxis Precision Medicines (PRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657645754","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657645754?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:40","pubTimestamp":1786106428,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Viatris (VTRS), Immunocore Holdings (IMCR) and Pra...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-viatris-vtrs-immunocore-holdings-imcr-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-viatris-vtrs-immunocore-holdings-imcr-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJT1NW94.SGD","LU1839511570.USD","BK4583","BK4137","IMCR","VTRS","LABU","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0320765992.SGD","LU0889565916.HKD","IE0002141913.USD","IE00B4R5TH58.HKD","IE0009355771.USD","IE00BFTCPJ56.SGD","XBI","PRAX","BK4581","XLV","BK4585","IBRN","LU0128526141.USD","HCSG","LU2087621335.USD","BK4139","BK4588","LU0029874061.USD","BK4505","BK4007","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657699655","title":"Analysts Are Bullish on These Healthcare Stocks: Immunocore Holdings (IMCR), Natera (NTRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657699655","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657699655?lang=en_us&edition=fundamental","pubTime":"2026-08-07 13:20","pubTimestamp":1786080009,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immunocore Holdings (IMCR) and Natera (NTRA) with bu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-immunocore-holdings-imcr-natera-ntra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-immunocore-holdings-imcr-natera-ntra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0012050646.USD","LU0345770308.USD","BK4139","BK4505","HELX","LU1064131342.USD","LU1988902786.USD","LU2065169927.USD","LU2065171402.SGD","IMCR","NTRA","LU2065170008.USD","LU0053671581.USD","LU2065171311.SGD","LU0345770993.USD","LU2065731478.USD","LU2324357040.USD","GNOM","LU0963586101.USD","LU2264538146.SGD","LU0106261612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657537356","title":"Needham Reaffirms Their Buy Rating on Immunocore Holdings (IMCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657537356","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657537356?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:35","pubTimestamp":1786030540,"startTime":"0","endTime":"0","summary":"Needham analyst Gil Blum maintained a Buy rating on Immunocore Holdings today and set a price target of $75.00. According to TipRanks, Blum is a 5-...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/needham-reaffirms-their-buy-rating-on-immunocore-holdings-imcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/needham-reaffirms-their-buy-rating-on-immunocore-holdings-imcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657632494","title":"Immunocore Holdings PLC Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657632494","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657632494?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:32","pubTimestamp":1786023175,"startTime":"0","endTime":"0","summary":"Immunocore Holdings PLC reports results for the quarter ended June 30 - Earnings SummaryImmunocore Holdings PLCIMCR.OQreported a quarterly adjusted loss of 2 cents per share for the quarter ended June","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4431Y1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","IMCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657639952","title":"Immunocore Publishes Corporate Presentation on Bispecific Soluble TCR Platform and Pipeline Across Oncology, Infectious and Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2657639952","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657639952?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:15","pubTimestamp":1786018523,"startTime":"0","endTime":"0","summary":"Immunocore publishes corporate presentation on bispecific soluble TCR platform and pipeline across oncology, infectious and autoimmune diseasesImmunocore highlighted KIMMTRAK as the standard of care i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL2qC4Qg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMCR","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657363361","title":"Earnings Flash (IMCR) Immunocore Posts Q2 Loss $0.02 a Share, vs. FactSet Est of $0.02 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657363361","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657363361?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:22","pubTimestamp":1786015333,"startTime":"0","endTime":"0","summary":"Earnings Flash (IMCR) Immunocore Posts Q2 Loss $0.02 a Share, vs. FactSet Est of $0.02 Loss","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638746","title":"UK's Immunocore Q2 EPS Misses Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638746","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638746?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:14","pubTimestamp":1786014856,"startTime":"0","endTime":"0","summary":"UK's Immunocore Q2 EPS misses estimatesOverviewUK biotech firm's Q2 KIMMTRAK revenue rose 18% yr/yr, driven by higher US and global salesQ2 adjusted EPS and net income missed analyst expectations; ope","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430HB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","HIK.UK","CHRS","IMCR","LU0889565916.HKD","EYPT","BK5011","IE00B0JY6N72.USD","BK4535","BK4585","BK4588","BK4007","LU0320765992.SGD","LU0109394709.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638220","title":"Immunocore Q2 FY26 Net Loss Narrows to $0.8 Million; Revenue Rises 18% to $115.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638220","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638220?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:12","pubTimestamp":1786014744,"startTime":"0","endTime":"0","summary":"Immunocore Q2 FY26 net loss narrows to $0.8 million; revenue rises 18% to $115.9 millionImmunocore posted Q2 net sales of $115.9 million, up 18% year over year, driven by higher volumes in the US and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL6RCk2d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMCR","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638619","title":"Immunocore Hldgs Q2 EPS $(0.02) Misses $0.02 Estimate, Sales $115.927M Beat $110.374M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638619","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638619?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:05","pubTimestamp":1786014328,"startTime":"0","endTime":"0","summary":"Immunocore Hldgs (NASDAQ:IMCR) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.02 by 200 percent. This is a 90 percent increase over losses of $(0.20) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60987550/immunocore-hldgs-q2-eps-0-02-misses-0-02-estimate-sales-115-927m-beat-110-374m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMCR","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680141","title":"Press Release: Immunocore Reports Second Quarter Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680141","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657680141?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014000,"startTime":"0","endTime":"0","summary":"Immunocore reports second quarter financial results and provides a business updateKIMMTRAK(R) (tebentafusp-tebn) net revenues of $115.9 million in Q2 2026, growing by 18% year-over-yearEnrollment in P","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","PROC","ATOM","CM","IMCR","R","BK4022","BK4505","BK4147","BK4232","BK4207","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656649536","title":"Immunocore Holdings PLC Expected to Post Earnings of 1 Cent a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656649536","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656649536?lang=en_us&edition=fundamental","pubTime":"2026-08-04 16:41","pubTimestamp":1785832879,"startTime":"0","endTime":"0","summary":"Immunocore Holdings PLC <IMCR.OQ> expected to post earnings of 1cent a share - Earnings PreviewImmunocore Holdings PLCIMCR.OQIMCR.Ois expected to  show a rise in quarterly revenue when it reports  res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL8N4410P3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","IMCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655794658","title":"Immunocore to Report Q2 Financial Results, Host Investor Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2655794658","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655794658?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:15","pubTimestamp":1785410127,"startTime":"0","endTime":"0","summary":"Immunocore to report Q2 financial results, host investor callImmunocore schedules second-quarter 2026 results for Aug. 6, 2026.Live webcast, conference call set for Aug. 6, 2026 at 8:00 a.m. EDT to di","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL59n3lH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014005.SGD","IE00BKPKM429.USD","BK4588","LU0314104364.USD","LU2095319765.USD","BK4585","BK4139","IE00BN0W2V16.EUR","LU2210150020.SGD","IMCR","BCDF","NDAQ","SG9999014013.SGD","IE00B3QW5Z07.USD","BK4505","BK4112","IE00BN0W2W23.USD","SG9999014039.USD","SG9999014021.USD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642473871","title":"The Bull Case For Immunocore Holdings (IMCR) Could Change Following New Brenetafusp Melanoma Data - Learn Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2642473871","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642473871?lang=en_us&edition=fundamental","pubTime":"2026-06-11 01:20","pubTimestamp":1781112014,"startTime":"0","endTime":"0","summary":"Immunocore Holdings recently reported updated Phase 1/2 data for its ImmTAC molecule brenetafusp in heavily pretreated advanced melanoma, showing encouraging survival and disease control outcomes that informed selection of a 160 mcg dose for its ongoing Phase 3 PRISM-MEL-301 trial.\nThe results presented at ASCO 2026 also suggested potential benefit in patients with primary PD-1 resistance and hinted at further upside from combinations, including with IL7, which could broaden the future role...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/the-bull-case-for-immunocore-holdings-imcr-could-change-foll","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/the-bull-case-for-immunocore-holdings-imcr-could-change-foll","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4528","IMCR","ARTY","BK4023","BK4585","BK4587","AIPO","BK4543","BK4588","CHAT","AGIX","BK4551","BK4139","AI","BK4505","AIYY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640383941","title":"Immunocore Holdings (IMCR) Gets a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2640383941","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640383941?lang=en_us&edition=fundamental","pubTime":"2026-06-04 08:10","pubTimestamp":1780531841,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Immunocore Holdings, with a price target of $100.0...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/immunocore-holdings-imcr-gets-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/immunocore-holdings-imcr-gets-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMCR","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640193774","title":"What Immunocore Holdings (IMCR)'s Phase 1 Brenetafusp Data and 160 mcg Dose Choice Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2640193774","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640193774?lang=en_us&edition=fundamental","pubTime":"2026-06-01 17:22","pubTimestamp":1780305722,"startTime":"0","endTime":"0","summary":"Immunocore Holdings recently reported updated Phase 1 results for its TCR bispecific brenetafusp in heavily pretreated HLA-A*02:01-positive advanced melanoma, showing a 6‑month overall survival rate of 87% and a disease control rate of 52%, and confirming 160 mcg as the dose for the ongoing Phase 3 PRISM-MEL-301 trial.\nThis early signal of durable disease control in a difficult-to-treat melanoma population highlights how brenetafusp could broaden Immunocore’s oncology franchise beyond...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/what-immunocore-holdings-imcrs-phase-1-brenetafusp-data-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/what-immunocore-holdings-imcrs-phase-1-brenetafusp-data-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4023","BK4528","AI","CHAT","AIYY","BK4505","IMCR","AIPO","CHH","ARTY","BK4139","BK4551","BK4142","AGIX","BK4543","BK4585","BK4587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640937163","title":"Immunocore Reports 14.3-Month Survival in Phase 1/2 Trial of Advanced Melanoma Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2640937163","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640937163?lang=en_us&edition=fundamental","pubTime":"2026-06-01 17:20","pubTimestamp":1780305622,"startTime":"0","endTime":"0","summary":"Immunocore  said Sunday its updated phase 1/2 study data showed its investigational therapy, brenetafusp, achieved a median overall survival of 14.3 months in heavily pretreated patients with advanced melanoma.The company said the study showed an overall response rate of 12% and a disease control rate of 52%.Overall survival rates were 87% at six months and 57% at 12 months, the company said.The drugmaker said patients receiving the 160mcg dose showed higher rates of clinical benefit, including overall survival, disease control, response rates and tumor reduction, compared with those treated with the 40mcg dose, supporting selection of the higher dose for the ongoing phase 3 trial of brenetafusp plus nivolumab in first-line advanced melanoma.Among patients with primary PD-1 resistance, median overall survival was 14.7 months, comparable to the broader study population, the company said.It added that a separate cohort of 10 patients treated with brenetafusp plus pembrolizumab, response ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0031619046.USD","BK4157","IE00B19Z4B17.USD","AEIS","IE00B7SZL793.SGD","BK4139","BK4505","LU1815336091.USD","IMCR","LU0757428866.USD","IE00B66KJ199.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640134986","title":"Immunocore presents updated results from Phase 1/2 trial of brenetafusp","url":"https://stock-news.laohu8.com/highlight/detail?id=2640134986","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640134986?lang=en_us&edition=fundamental","pubTime":"2026-06-01 05:25","pubTimestamp":1780262705,"startTime":"0","endTime":"0","summary":"Immunocore (IMCR) announced updated results from its Phase 1/2 trial evaluating brenetafusp in patients with heavily pretreated advanced melanoma. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunocore-presents-updated-results-from-phase-1-2-trial-of-brenetafusp-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunocore-presents-updated-results-from-phase-1-2-trial-of-brenetafusp-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4505","IMCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639988555","title":"Immunocore says Phase 1 brenetafusp data show 87% 6-month survival in advanced melanoma patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2639988555","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639988555?lang=en_us&edition=fundamental","pubTime":"2026-05-31 20:00","pubTimestamp":1780228818,"startTime":"0","endTime":"0","summary":"Immunocore presented updated Phase 1/2 results for brenetafusp in heavily pretreated advanced melanoma at the 2026 ASCO Annual Meeting.The study showed meaningful survival and disease control signals in patients who had progressed on prior PD-1 therapy.Findings supported selecting the 160 mcg dose for the ongoing Phase 3 PRISM-MEL-301 first-line advanced melanoma trial.Activity appeared consistent in difficult-to-treat patients, including those with primary resistance to PD-1 therapy.Safety was described as generally tolerable, with side effects characterized as predictable and manageable across monotherapy and combination use.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260531:nNDL4vSds5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BN0W2W23.USD","BK4112","SG9999014039.USD","IE00BN0W2V16.EUR","BK4139","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","SG9999014005.SGD","LU2095319765.USD","BK4505","SG9999014013.SGD","LU2210150020.SGD","SG9999014021.USD","IE00BKPKM429.USD","LU0314104364.USD","IE00BGHQF748.EUR","NDAQ","BK4585","BK4588","IMCR","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immunocore.com","stockEarnings":[{"period":"1week","weight":0.0608},{"period":"1month","weight":0.0522},{"period":"3month","weight":0.2584},{"period":"6month","weight":0.1102},{"period":"1year","weight":0.1167},{"period":"ytd","weight":0.0452}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0191},{"period":"3month","weight":0.0227},{"period":"6month","weight":0.1061},{"period":"1year","weight":0.1951},{"period":"ytd","weight":0.1183}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in Phase 1 clinical trial for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.031356},{"month":2,"riseRate":0,"avgChangeRate":-0.062034},{"month":3,"riseRate":0.333333,"avgChangeRate":0.007534},{"month":4,"riseRate":0.5,"avgChangeRate":0.010332},{"month":5,"riseRate":0.5,"avgChangeRate":-0.014019},{"month":6,"riseRate":0.5,"avgChangeRate":0.000567},{"month":7,"riseRate":0.833333,"avgChangeRate":0.07593},{"month":8,"riseRate":0.5,"avgChangeRate":0.00228},{"month":9,"riseRate":0.4,"avgChangeRate":-0.024202},{"month":10,"riseRate":0.4,"avgChangeRate":0.002617},{"month":11,"riseRate":0.8,"avgChangeRate":0.095366},{"month":12,"riseRate":0.2,"avgChangeRate":-0.012917}],"exchange":"NASDAQ","name":"Immunocore Holdings plc","nameEN":"Immunocore Holdings plc","securityTypeName":"DR","adrRate":"1:1"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunocore Holdings plc(IMCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immunocore Holdings plc(IMCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immunocore Holdings plc,IMCR,Immunocore Holdings plc股票,Immunocore Holdings plc股票老虎,Immunocore Holdings plc股票老虎国际,Immunocore Holdings plc行情,Immunocore Holdings plc股票行情,Immunocore Holdings plc股价,Immunocore Holdings plc股市,Immunocore Holdings plc股票价格,Immunocore Holdings plc股票交易,Immunocore Holdings plc股票购买,Immunocore Holdings plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunocore Holdings plc(IMCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immunocore Holdings plc(IMCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction